Dolores Steverlynck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dolores Steverlynck has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Nicolás Schöngut-Grollmus
Núcleo de Investigación en Interacciones Sociales, Facultad de Salud y Ciencias Sociales Universidad de Las Américas Santiago Chile
2 shared publications - Fernanda Manríquez
Universidad Diego Portales Santiago Chile
1 shared publication - Gabriela M. Repetto
Rare Diseases Program, Center for Genetics and Genomics, Institute of Science and Innovation in Medicine, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile
1 shared publication - Sebastian Rojas Navarro
Universidad Andres Bello
1 shared publication
Latest Publications
- 23 August 2026
- Published by Wiley in Sociology of Health & Illness
- Vol. 48 (7) , e70255
Rare Diseases as Epistemic Objects: Exploring the Moral Role of Health Systems
This article explores how rare diseases reveal the moral and epistemic foundations of healthcare systems. Based on narrative interviews with 11 Chilean patients and 10 professionals, this study shows how the absence of standardised protocols—such as clinical guidelines, treatment pathways and referral standards—exposes informal, discretionary and morally complex decision‐making processes. Contrary to the ideal of evidence‐based care, rare disease treatment often relies on personal networks, institutional gaps and improvisation. We frame rare diseases as epistemic objects, conditions that challenge classification systems and highlight the normative assumptions behind health decisions. Introducing the concept of decisional justice, we examine how health systems support (or fail to support) fair and accountable decision‐making. Patients become epistemic activists, whereas professionals navigate fragmented institutions with little guidance. Rare diseases act as diagnostic tools that expose structural inequities and the invisibility of certain conditions. They reveal how ignorance can translate into neglect, shifting responsibility to individuals and deepening disparities. We argue that healthcare systems are not only logistical but also moral infrastructures, shaping what can be known and acted upon. Thus, health justice must also involve moral recognition and epistemic inclusion, not just resource distribution.
- 23 August 2026
- Published by Wiley in Sociology of Health & Illness
- Vol. 48 (7) , e70255
Rare Diseases as Epistemic Objects: Exploring the Moral Role of Health Systems
This article explores how rare diseases reveal the moral and epistemic foundations of healthcare systems. Based on narrative interviews with 11 Chilean patients and 10 professionals, this study shows how the absence of standardised protocols—such as clinical guidelines, treatment pathways and referral standards—exposes informal, discretionary and morally complex decision‐making processes. Contrary to the ideal of evidence‐based care, rare disease treatment often relies on personal networks, institutional gaps and improvisation. We frame rare diseases as epistemic objects, conditions that challenge classification systems and highlight the normative assumptions behind health decisions. Introducing the concept of decisional justice, we examine how health systems support (or fail to support) fair and accountable decision‐making. Patients become epistemic activists, whereas professionals navigate fragmented institutions with little guidance. Rare diseases act as diagnostic tools that expose structural inequities and the invisibility of certain conditions. They reveal how ignorance can translate into neglect, shifting responsibility to individuals and deepening disparities. We argue that healthcare systems are not only logistical but also moral infrastructures, shaping what can be known and acted upon. Thus, health justice must also involve moral recognition and epistemic inclusion, not just resource distribution.
- 10 December 2025
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (6) , e70154
Genetic testing as moral technology: Navigating legitimacy, uncertainty, and access in rare disease diagnosis
Genetic testing is often portrayed as a neutral tool for clinical clarification. However, in the context of rare diseases, it plays a far more complex role in the moral, bureaucratic, and social experiences of patients and families. Drawing on qualitative research conducted in Chile, this article explores how genetic testing is not only a diagnostic resource but also a symbolic and institutional technology that shapes how care, legitimacy, and identity are negotiated across multiple domains. We analyze 11 narrative interviews with patients and family members affected by rare diseases, alongside 10 interviews with healthcare professionals, including geneticists and clinicians, and two hybrid forums. Using a grounded, interdisciplinary approach informed by Science and Technology Studies (STS) and medical sociology, we identify four key themes: (1) the moral resolution offered by diagnosis after long periods of uncertainty; (2) structural barriers to accessing testing, including social capital and institutional discretion; (3) the epistemic ambiguity of genetic information, especially in cases of inconclusive results; and (4) the mobilization of diagnoses beyond the clinic, including in education, legal systems, and reproductive decisions. Our findings suggest that genetic testing functions as a moral and classificatory technology: it produces recognition, redistributes responsibility, and serves as a resource for navigating fragmented care systems. For genetic counselors, this research offers insights into how patients and families interpret, act on, and negotiate the consequences of genetic information. Understanding the broader moral and institutional landscape in which testing occurs can enhance counseling practices, particularly in under‐resourced or structurally unequal contexts. This study contributes to growing efforts to embed genetic counseling in a wider social and ethical framework. By attending to how genetic testing is lived, contested, and deployed, we highlight the need for a counseling practice that is attuned to both genomic data and the realities of care.
- 10 December 2025
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (6) , e70154
Genetic testing as moral technology: Navigating legitimacy, uncertainty, and access in rare disease diagnosis
Genetic testing is often portrayed as a neutral tool for clinical clarification. However, in the context of rare diseases, it plays a far more complex role in the moral, bureaucratic, and social experiences of patients and families. Drawing on qualitative research conducted in Chile, this article explores how genetic testing is not only a diagnostic resource but also a symbolic and institutional technology that shapes how care, legitimacy, and identity are negotiated across multiple domains. We analyze 11 narrative interviews with patients and family members affected by rare diseases, alongside 10 interviews with healthcare professionals, including geneticists and clinicians, and two hybrid forums. Using a grounded, interdisciplinary approach informed by Science and Technology Studies (STS) and medical sociology, we identify four key themes: (1) the moral resolution offered by diagnosis after long periods of uncertainty; (2) structural barriers to accessing testing, including social capital and institutional discretion; (3) the epistemic ambiguity of genetic information, especially in cases of inconclusive results; and (4) the mobilization of diagnoses beyond the clinic, including in education, legal systems, and reproductive decisions. Our findings suggest that genetic testing functions as a moral and classificatory technology: it produces recognition, redistributes responsibility, and serves as a resource for navigating fragmented care systems. For genetic counselors, this research offers insights into how patients and families interpret, act on, and negotiate the consequences of genetic information. Understanding the broader moral and institutional landscape in which testing occurs can enhance counseling practices, particularly in under‐resourced or structurally unequal contexts. This study contributes to growing efforts to embed genetic counseling in a wider social and ethical framework. By attending to how genetic testing is lived, contested, and deployed, we highlight the need for a counseling practice that is attuned to both genomic data and the realities of care.